prof. Valerie Fonteyne
- ORCID iD
-
0000-0001-6724-1595
Show
Sort by
-
- Journal Article
- A1
- open access
Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effects
-
- Journal Article
- A1
- open access
Update of the EORTC health-related quality of life modules for bladder cancer : phase 1–2 of the development process
-
- Journal Article
- A1
- open access
Pelvic lymph node dissection during radical prostatectomy for prostate cancer : harms versus benefits
-
- Journal Article
- A1
- open access
Does it make sense to perform prostate magnetic resonance imaging in men with normal PSA (<4 ng/mL)?
-
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE) : a systematic review and individual patient data meta-analysis from the X-MET collaboration
-
- Journal Article
- A1
- open access
Health-related quality of life outcomes of salvage metastasis-directed treatment versus elective nodal treatment for oligorecurrent nodal prostate cancer : a secondary analysis of the phase 2, open-label PEACE V–STORM randomized trial
-
Prostate cancer
-
- Journal Article
- A1
- open access
PSMA PET/CT-guided pelvic lymph node dissection in patients with unfavorable intermediate- or high-risk prostate cancer
-
- Journal Article
- A1
- open access
Using machine learning to predict patient-reported symptom clusters in prostate cancer patients receiving radiotherapy
-
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial